EcoDrugPlus

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSPNYG00000007492
Gene Symbol: PTK2B
3 Cross references
195 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSPNYG00000003588
Gene Symbol: PTPN11
3 Cross references
251 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPNYG00000006016
Gene Symbol: PTPRB
4 Cross references
203 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSPNYG00000009936
Gene Symbol: PTPRB
4 Cross references
189 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSPNYG00000023875
Gene Symbol: LOC102207217
3 Cross references
159 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSPNYG00000021857
Gene Symbol: LOC102203088
3 Cross references
197 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSPNYG00000016985
Gene Symbol: P2RX3
3 Cross references
192 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSPNYG00000007433
Gene Symbol: P2RX7
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSPNYG00000007559
Gene Symbol: P2RY1
3 Cross references
190 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSPNYG00000015295
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSPNYG00000019587
Gene Symbol: LOC102208435
3 Cross references
199 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSPNYG00000013178
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).